As shown in Figure 8, we, for the first time, reported that the potent pro‐IBD effect of MCT4 stems from its ability to globally upregulate inflammatory factors and attenuate ZO‐1‐mediated intestinal barrier function in IECs through regulating two key transcription factors, NF‐κB and CREB, respectively. The gene discussed is TJP1; the disease is inflammatory bowel disease.